青岛海发健康投资控股公司负责人表示，海发健康控股重点布局生命健康产业赛道，将发挥自身优势资 源与京东健康在更多领域展开全面合作，实现优势互补、互利共赢。 近日，京东健康与青岛海发健康投资控股公司达成战略合作，正式获得安宫牛黄丸双天然全渠道代理 权。此次合作标志着京东健康在医药供应链领域的进一步深耕，双方将共同推动该产品在线上线下全渠 道市场的拓展，打开新的增长空间。 目前，京东健康已构建起覆盖线上线下的整合营销与服务体系。基于自身的用户洞察与精准营销能力， 京东健康能够实现药品与潜在需求人群的高效匹配，提升营销效率。此外，依托京东互联网医院的医疗 资源，还可为用户提供在线问诊、续方购药及送药上门等一站式健康服务，进一步延伸药品服务的价值 链。 合作达成后，京东健康将为其旗下安宫牛黄丸提供全渠道代理销售解决方案，依托自身线上线下一体化 的医药供应链服务体系，助力该产品覆盖更广泛的市场与用户群体。通过此次合作，京东健康不仅提升 了自身的一体化运营与精益化管理水平，也进一步强化了定制化供应链服务能力，为合作伙伴带来更多 元、高效的选择。 京东健康医药业务负责人表示，京东健康将持续发挥"超级医药供应链"能力优势，整合 ...

来源：环球时报 美国国会下属的美中经济与安全审查委员会成员利兰·米勒说，政府希望建立一个有印度和其他盟友参 与的供应链，在特定领域实现对中国的"脱钩"。考虑到生产用于制造药物的起始化合物利润微薄且收益 低下，这将是一项几乎不可能完成的事业。 新加坡亚洲新闻台11月27日文章，原题：中国掌握着全球制药市场的所有牌中国在医药供应链中扮演着 重要角色，美国和其他国家在很大程度上依赖中国生产其药品的基础原料。由于自20世纪50年代开始发 展的庞大且商品化的产业，中国在全球药品供应链中发挥着举足轻重的作用。中国是被称为关键起始物 料（KSM）的化合物的重要生产国，这些化合物用于生产被称为活性药物成分（API）的原料。 中国在20世纪80年代开始放开生产，同时也对其他经济领域进行改革，重点是降低成本。一篇媒体报道 援引一名美企高管的话说，如果美国公司试图复制原材料供应链，其成本将上涨50%。制药行业的情况 很可能类似。事实上，中国在许多关键领域都占据着主导地位。（作者Juliana Liu，宋波译） 关于美国对中国依赖的确切程度，目前尚缺乏确凿数据。大型制药商没有太多动力详细说明这种依赖的 深度。较可靠的估计数据来自美国 ...

证券日报网讯药易购（300937）11月19日在互动平台回答投资者提问时表示，随着冬季呼吸道疾病进入 高发期，公司密切关注医药市场动态，积极发挥医药流通企业的供应链优势，基于公司的药品稳定供应 与保障体系建设并结合市场需求的波动情况，动态调整药品各类库存，致力于保障终端药品的稳定供 应。 ...

Core Points - The Trump administration has confirmed it does not plan to impose tariffs on foreign generic drugs, which account for approximately 90% of the medications used by Americans daily [1][2] - This decision marks a significant reduction in the scope of the Department of Commerce's investigation under the "Section 232" national security framework regarding pharmaceutical products [2] - There are internal divisions within the government regarding the imposition of tariffs on generic drugs, with some officials warning that such tariffs could lead to increased consumer costs and potential drug shortages [3][4] Group 1 - The decision to exclude generic drugs from tariff lists is a reversal of previous commitments made by Trump to bring essential drug production back to the U.S. [2] - The administration is still pursuing the goal of "manufacturing return," considering federal funding or loans for domestic manufacturers of critical generic drugs [1][2] - The potential use of funds from foreign governments, such as Japan, as part of tariff agreements is under consideration, although infrastructure funding has not yet been established [1] Group 2 - Some officials argue that high tariffs on generic drugs may not make domestic production profitable due to the low production costs in countries like India, which supplies nearly half of U.S. generic drugs [3] - Conversely, protectionist officials believe that reliance on foreign suppliers poses a national security risk and that tariffs could incentivize domestic production [3] - The government is adopting a detailed approach to reshape the generic drug manufacturing landscape to avoid supply chain disruptions experienced during the COVID-19 pandemic [3]

Core Points - The company, Realcan Pharmaceutical Group Co., Ltd., was established in December 2009 and is registered in Yantai, Shandong Province with a registered capital of RMB 1,504.71 million [2][3][7] - The company aims to enhance health services through innovation and compliance, focusing on a digital, integrated, and intelligent pharmaceutical supply chain [8][9] - The company has undergone several rounds of public and private share issuance, with the latest being a non-public offering in 2016 [3][10] Company Structure - The company operates as a joint-stock limited company, with its legal representative being the chairman of the board [4] - The company has a total of 150,471.0471 million shares issued, all of which are ordinary shares [11][12] - The company is governed by its articles of association, which outline the rights and responsibilities of shareholders, directors, and senior management [4][16] Business Operations - The company's business scope includes the sale of various medical and pharmaceutical products, including medical devices, health foods, and agricultural products [9] - The company is committed to fulfilling its social responsibilities as a key player in the national pharmaceutical supply chain [8] Shareholder Rights and Responsibilities - Shareholders have the right to receive dividends, participate in shareholder meetings, and access company documents [16][17] - Shareholders are required to report any changes in their shareholding that exceed 3% [22][23] - The company has provisions to protect shareholder interests and ensure compliance with legal obligations [19][20]